🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2024-516625-31-00
Completed Phase I

Subcutaneous Trastuzumab Deruxtecan Phase 1 Trial.

2024-516625-31-00 · tracked via the Priya Life Science EU tracker
Sponsor
Daiichi Sankyo Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
30/10/2025
Enrollment target
24
Sites
Spain, France

Condition studied

Advanced Solid Tumor

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2024-516625-31-00 on CTIS ↗ ← All trials in the EU